Latham Advises Gossamer Bio on Up to US$250 Million Structured Private Placement, Including US$150 Million of Committed Capital
Gossamer Bio (GOSS) plans a private placement of up to $250M, including $150M committed capital. The deal involves new and existing investors and is contingent on FDA actions for seralutinib. Latham & Watkins advised the company. The financing follows Gossamer's reacquisition of seralutinib rights and precedes its planned NDA submission in September 2026.
How this was made
The 30-second read
Why it matters
The $250 M private placement, contingent on regulatory approval, provides runway for NDA filing and commercialization, likely improving liquidity and valuation.
Market read
First‑time disclosure of a sizable capital raise for a biotech awaiting FDA approval; immediate relevance for traders and investors.
What to watch
Potential dilution from warrants and the contingent nature of the second closing may temper price gains.
Background
Gossamer Bio is a clinical‑stage company developing seralutinib for PAH and PH‑ILD, recently reacquired worldwide rights to the drug.
Ticker impact
Gossamer Bio announced a private placement to raise up to $250 million, with $150 million committed, contingent on FDA acceptance of its seralutinib NDA.
Potential short‑term upside as investors price in the new cash and FDA‑linked milestones.
Large, fresh financing disclosed for the first time; market typically reacts positively to substantial capital infusions for clinical‑stage biotech.
Market effects
Adds funding depth to the pulmonary hypertension biotech niche, may spur competitor activity.
Supports the US biotech financing environment, modest impact on Nasdaq biotech indices.
Highlights continued investor appetite for high‑risk, high‑reward clinical‑stage therapeutics.
Counterpoint
If the FDA delays the NDA, the raised capital could dilute existing shareholders without near‑term upside.
Key entities
- CompanyGossamer Bio, Inc.
Clinical‑stage biopharma developing seralutinib.
- Law FirmLatham & Watkins LLP
Legal advisor on the financing transaction.
